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Abstract. To investigate a possible role of cytokines in parvovirus-mediated 
suppression of tumorigenesis, we tested in cell culture whether parvoviruses are 
able to induce interferon (IFN)-~, tumor necrosis factor (TNF)-a or interleukin-6 
(IL-6). Infection of rodent or human cells with the parvoviruses minute virus of 
mice (MVM), H-1 or adeno-associated virus (AAV) types 2 or 5 failed to induce 
expression of the luciferase or J3-galactosidase reporter genes transfected into these 
cells as constructs containing an IFN-J3 promoter. Parvoviruses did weakly induce 
synthesis of TNF-~ and of IL-6 in cell culture and could slightly enhance synthesis 
of these cytokines when induced by other agents. These in vitro data suggest that 
the rather unspecific tumor-suppressive properties of parvoviruses are unlikely to 
be attributable tostimulation of the synthesis of IFN, TNF or IL-6. 
Introduction 
Parvoviruses ofvertebrates have a single-stranded DNA genome of about 5000 bp 
and can be divided into autonomously replicating viruses [such as H-l, B-19, 
minute virus of mice (MVM), Aleutian disease virus (ADV), mink enteritis virus 
(MEV)] and adeno-associated viruses (AAV), which depend for their replication 
on factors provided by helper viruses [adenoviruses, herpes viruses, or vacciniavi- 
rus; (Cukor et al. 1984; Siegl et al. 1985; Schlehofer et al. 1986)] or specific cellular 
conditions related to factors induced by genotoxic stress (Schlehofer et al. 1983; 
Heilbronn et al. 1985; Yakobson et al. 1987; Yalkinoglu et al. 1988; Berns and 
Bohensky, 1987). 
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A unique property of the parvoviruses i  their capacity to suppress tumors in 
vivo and to inhibit cellular transformation i  vitro (Rommelaere 1990; Romme- 
laere and Tettersall 1990; Rommelaere and Cornelis 1991). The mechanism of the 
tumor-suppressive effects of parvovirus infections i not yet understood, but in the 
last few years several aspects of the interference of parvoviruses with cell 
transformation in vitro have been described: AAV infections inhibit mutagenesis 
(Schlehofer and Heilbronn 1990), inhibit carcinogen- or virus-induced DNA 
amplification (Schlehofer et al. 1983; Heilbronn et al. 1985; Schlehofer et al. 1986; 
Schmitt et al. 1989), and selectively kill "initiated" (e.g., carcinogen-treated) cells 
(Heilbronn et al. 1984). Autonomously replicating parvoviruses (H-l, MVM) 
preferentially kill transformed cells (Mousset and Rommelaere 1982; Chen et al. 
1986; Cornelis et al. 1988a; Cornelis et al. 1986; Mousset et al. 1986; Faisst et al. 
1989; Salom~ et al. 1990; Guetta et al. 1990) and their nonstructural proteins are 
cytotoxic essentially in tumorigenic cells (Cornelis et al. 1988 b; Brandenburger t 
al. 1990; Caillet Fauquet et al. 1990). 
Little is known concerning the mechanism of inhibition of tumorigenesis in 
vivo. Stimulation by parvovirus infection of immunological functions of the host 
leading to oncosuppression seems not to be very likely: even AAV with large 
deletions (up to 70%) within its genome was shown to inhibit oncogenicity of 
adenoviruses (de la Maza and Carter 1981) and there is no simple correlation 
between parvovirus H-1 titer and inhibition of tumors induced by 7,12-dimethyl- 
benz(a)anthracene i  hamsters (Toolan et al. 1982). 
Aside from its antiviral action interferon (IFN) is known to act cytostatically 
on some tumor cells (for review see Clemens and McNurlan 1985). Viruses might 
contribute to the inhibition of cell transformation byinduction of IFN in their host 
cells. However, as far as parvoviruses have been studied, they proved to be 
inefficient inducers of IFN in vivo (Kilham et al. 1968; Harris et al, 1974; 
Darrigrand et al. 1984; Wiedbrauk et al. 1986a, b). Furthermore, the anticarcino- 
genic activity of AAV in vivo could not be achieved by poly(dI-dC) (de la Maza and 
Carter 1981), which is known to efficiently induce IFN. 
Growth inhibition of some carcinoma cells also has been shown by the 
biological response modifier interleukin-6 [IL-6; synonym: IFN-~2; (Chen et al. 
1988)]. It can be induced by virus infection and by other cytokines, e.g., tumor 
necrosis factor (TNF; Kohase et al. 1986; Le and Vilcek 1989; Sehgal et al. 1989) 
and plays an important role in immune response regulation (Sehgal et al. 1989). IL- 
6 acts synergistically with TNF and IL-1 and is involved in T cell activation (Le and 
Vilcek 1989; Billiau et al. 1991). 
TNF-a is another potent pleiotropic response modifier (Old 1985; Beutler and 
Cerami 1989) in inflammatory and immunological host defense reacions. It was 
first discovered by its antitumor activity in mice (Carswell et al. 1975). TNF 
enhances the cytotoxic activity of NK cells and macrophages and causes necrosis 
and regression of some solid tumors in vivo. Therefore it has been used as an 
anticancer agent. TNF can be induced by different types of infectious agents, i.e., 
bacteria nd viruses (Carswell et al. 1975; Berent et al. 1986; Aderka et al. 1986; 
Lorence et al. 1988; Ray et al. 1988). The biological activities of TNF partially 
overlap with those of IFN, e.g., antiviral activity and growth inhibitory effects. 
These effects are probably mediated by IFN-~ (Jacobsen et al. 1989). 
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Methods and results 
To assess in vitro a possible role of IFN in parvovirus-mediated suppression of cell 
transformation a d tumorigenesis, we tested the effect of infection by parvoviruses 
on the murine IFN-[3 promoter transfected into human (HEp-2) and murine 
(C243) culture cells as a very sensitive indicator system (Ohno and Taniguchi 1983; 
Zinn et al. 1983; Maroteaux et al. 1983; Fujita et al. 1985; Goodburn et al. 1985; 
Goodburn et al. 1986; Dinter and Hauser 1987; and see below). The parvoviruses 
AAV types2 and 5, H-I, MVM (prototype strain), adenovirus type2, and 
Newcastle disease virus (NDV, for control purposes) were used in the experiments. 
To establish cellular clones containing an inducible IFN-[3 promoter, an 
EcoRI/PstI fragment of the murine IFN-]3 locus spanning approximately 1300 to 
+6 relative to the transcriptional start site and, thus, containing all 5' upstream 
sequences necessary for virus induction was cloned into pBlueluc yielding 
pBlueluc]315. The same fragment was also cloned into pSVM-1 leading to plasmid 
pSVM]31. The human IL-6 promoter (a kind gift of Dr. W. Fiers) was cloned as a 
1200-bp BamH1/XhoI fragment into pSVM-1, pSVM-1 contains the E. coli [3-gal 
gene, and pBlueluc ontains the firefly luciferase gene. Both genes are fused to the 
SV40 t intron and the polyadenylation site cloned into the pBluescript KSM13+ 
vector (Stratagene, Heidelberg, Germany). Transfection experiments were carried 
out according to the method of Chen and Okayama (Chen and Okayama 1987) 
with minor modifications. 
From C243 murine fibroblasts [transformed by Moloney sarcoma virus; high 
IFN-producing capacity; (Oie et al. 1972)] that were cotransfected with pBlue- 
lucl315 and pSV2Neo (Southern and Berg 1982) and selected with G418 (BRL, 
Berlin, Germany), we obtained clone Mu[315. C243 cells cotransfected with 
pBlueluc[315, pSVMIL6 and pSV2Neo resulted in clone IL61315. HEp-2 (human 
laryngeal carcinoma cell line) cells were cotransfected with pBlueluc]315 and the 
construct pSV2Pac, conferring puromycin resistance (Vara et al. 1985; 1986). After 
selection with puromycin, clone Hep 1300Luc was isolated. 
As a specificity control, both parental cell lines (C243, HEp-2) were also 
transfected transiently and stably with pSVM 1, pBlueluc and pSVM[31. In contrast 
to pSVM1, pBlueluc showed a low, but significant signal over background which 
could be reduced to background level by cloning either the murine IFN-[3 
promotor or the SV40 polyadenylation site in front of the luciferase gene. These 
results indicated that a small number of transcripts originated from the pBluescript 
vector. 
To test for induction of luciferase activity from the IFN-[3 promoter, Mu[315 
cells, IL61315 cells, and Hepl300Luc were seeded into 12- or 24-well dishes and 
infected with AAV type 2 [heated to 60 ~ C for 30 min to inactivate adenovirus (used 
for propagation of AAV)], with AAV types 2 or 5 (CsCl-purified viruses), H-l, 
adenovirus type 2 (ad-2), and Newcastle disease virus (NDV), or treated with TNF 
(500 ng/ml). NDV infection or treatment with TNF was used as "positive" controls 
(Lorence et al. 1988; Ray et al. 1988) and adenovirus infection (with live or heat- 
inactivated virus) was performed to analyze any effects of adenovirus in 
experiments with the heat-"inactivated" AAV type 2. After incubation overnight, 
cells were inoculated with virus at the multiplicities of infection (m.o.i.) indicated 
in Fig. 1 and incubated for 1 or 2 more days. At 24 or 48 h, cells were harvested for 
determination of luciferase induction (for details see legend to Fig. 1). After 
adjusting for protein concentrations of the cell extracts, luciferin was mixed with 
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Fig. 1 a, 5. Relative luciferase activity from the interferon-J3 (IFN-I3) promoter after parvovirus 
infection of human and murine cells. Cells containing the luciferase gene under the control of the 
IFN-!3 promoter [Hepl300Luc (a) and Mu]315, IL61315 (b), see text] were grown on plastic in 
Eagle's minimal essential medium (Dulbecco's modification; Biochrom, Berlin, Germany) 
supplementd with 10 % fetal calf serum (Gibco, Eggenstein, Germany) and antibiotics. Cells were 
incubated at 37 ~ C in a humidified atmosphere (5% CO2). For determination f luciferase activity 
from the IFN-i3 promoter, cells were seeded into 12- or 24- well dishes (Greiner, Ntirtingen, Ger- 
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extracts and assayed for induction of  luciferase. As shown in Fig. 1 (a, b), none of 
the parvoviruses, AAV types 2 and 5, H-1 or MVM induced luciferase product ion 
from the IFN-[3 promoter.  This is in contrast o infection with NDV (notably in the 
murine cells), with adenovirus type 2, or to treatment with TNF  (positive controls). 
Figure 1 a demonstrates in addition that NDV or adenovirus infection can enhance 
TNF- induced stimulation from the IFN-[3 promoter,  whereas infection with AAV 
or H- 1 does not influence the level of  luciferase induced by TNE Similarly, the [3- 
galactosidase r porter gene driven by the IFN-13 promoter was not induced in cells 
infected with parvoviruses (data not shown). 
There were several reasons for measuring transient expression of  luciferase 
activity using the IFN-[3 promoter  to determine the capability of  induction of IFN-  
[3 by parvoviruses. First, the luciferase protein was reported to have a very short 
half-life in vivo because it contains a peroxisomal targeting sequence (Keller et al. 
1987). Second, biological half-life analysis howed that luciferase is degraded more 
rapidly than other indicator proteins, e.g., chloramphenicol acetyl transferase 
(CAT) or [3-galactosidase (13-gal) (Thompson et al. 1991; cf., Brasier et al. 1989). 
Third, a kinetics analysis of  TNF- induced stimulation of  luciferase in Hep-2 cells 
revealed that its maximal expression takes place 6 h after treatment decreasing to 
50% 6h later (M. Rentrop, unpublished results). On the other hand, "natural" 
IFN-[3 protein is very stable in culture medium and accumulates in contrast o 
transient luciferase activities as measured in our system. These facts render 
transient assays more reliable when determining induction of  IFN-[3. The 
extremely high sensitivity in detecting induction of  the IFN-13 promoter in the 
system used here was recently demonstrated by Jacobsen et al. (1989) who showed 
that luciferase activity induced by TNF  via the IFN-13 promoter  was detectable at 
conditions where IFN-[3 mRNA was detectable only by polymerase chain reaction 
analysis. 
For control purposes, we tested the sensitivity of  parvoviruses to the antiviral 
effect of  I FN  in L929 cells (for MVM infection) and HeLa cells (for H-1 infection), 
many; 1 x 104 or 3 • 10 4 cells per well, respectively). After incubation overnight, PBS-washed cells 
were inoculated with virus [AAV types 2 or 5 (CsCl-purified): 100 TCIDs0 units/cell; AAV type 2 
(heated to 60~ for 30 min to inactivate adenovirus used for propagation of the helper virus- 
dependent AAV; "AAV-2(i)": 10 TCIDs0 units/cell; H-1: 10 pfu/cell; MVM: 10 pfu/cell; adenovi- 
rus type 2:1 pfu/cell]; NDV 0.1 H.U./cell, or treated with TNF (500 ng/ml). NDV infection or 
treatment with TNF were used as "positive" controls for C243 or Hep-2 cells, respectively. 
Adenovirus infection [with live or heat-inactivated virus (as above) "Ad-2(i)"] was performed to 
analyze ffects of adenovirus in experiments with heat-"inactivated" AAV type 2 ["AAV-2(i)"]. 
After adsorption at 37~ for 1 h medium was replenished and cells were incubated (37~ 5% 
CO2) for 1 or 2 more days. At 24 or 48 h after infection, cells were washed with PBS and removed 
using a cell scraper. Cells were then pelletted and chilled to - 70 ~ C followed by two more rounds 
of freezing and thawing. Cell extracts were suspended in 250 mM TRIS/HCI (pH 7.8), mixed 
thoroughly and spun down (low-speed centrifugation). Supernatants were analyzed for the 
concentration f protein using the Bio-Rad protein assay (Bio-Rad, Miinchen, Germany). After 
adjusting the protein concentrations of the cell extracts to a bovine serum albumin standard, 
250 t~1 of Luciferin [Boehringer, Mannheim, Germany; 0.25 mM in 15 mM MgC12, 25 mM TRIS/ 
HC1 (pH 7.8), 5 mM ATP]) was mixed with extracts and assayed for induction of luciferase in a 
"Lumat" analyzer (Berthold, Wildbad, Germany). a Relative induction of luciferase in 
HEp 1300Luc ells, 24 h after infection. Luciferase activity as induced by TNF is set as 1. Columns 
represent means of triplicate experiments, b Relative induction of luciferase in Mu[315 or IL613 t5 
cells, 24 or 48 h after infection, as indicated. The induction level of transcription from the IFN-[3 
promoter by NDV infection is set as 1 
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Fig. 2a, b. Analysis of induction of tumor necrosis factor-a (TNF-a) in THP-1 or RAW264 cells 
after parvovirus infection. THP-1 cells grown in RPMI 1640, 10 % fetal calf serum (a) or RAW264 
cells grown in D-MEM, 10% fetal calf serum (b) were infected with AAV or H-1 or treated with 
lipopolysaccharide (LPS, 10 g/ml; from Salmonella Minnesota," Sigma, Geisenhofen, Germany), 
respectively, and tested for induction of TNF. Cells in plastic dishes (RAW264:2.5 • 105/9cm~; 
6 THP-I: 1• /ml) were infected or treated, respectively. In some experiments cells were 
additionally treated with LPS 1 h prior to ("LPS + AAV-2 or H-l") or after ("AAV-2 or H- 
I + LPS") infection. Cells were washed with PBS and inoculated with purified virus (cf. Fig. l; 
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Fig. 3. Analysis of induction of interleukin-6 (IL-6) by parvovirus infection in HeLa cells. HeLa 
5 2 cells (2.5 • 10 /9 cm well of a six- well plastic dish) were infected with AAV type 2 or H-1 (m.o.i.'s 
in Fig. 1 and 2, respectively) or treated with TNF [500 ng/ml (similar results with 2 g/ml)] and 
assayed (24 h after infection) for the presence of IL-6 in the supernatant. In some experiments cells 
were additionally treated with TNF 1 prior to ("TNF + AAV-2 or H-I") or after ("AAV-2 or H- 
I +TNF") infection. IL-6 concentration was determined using the InterTest-6X Human IL-6 
ELISA (Genzyme, Cambridge, Mass., USA) 
respectively. Cells were treated with 1000IU/ml or 100IU/ml  of murine 
(L929 cells) or human (HeLa cells) IFN-a/[3 or murine IFN-•, or mock-treated. 
After 18 h, cells were inoculated with MVM (10 to 0.0001 pfu/cell) or H-1 (100 to 
0.0001 pfu/cell). Uninfected cells or cells infected with vesicular stomatitis virus 
(VSV) were used as negative and positive controls, respectively. Cells were checked 
for cytopathic effects 3 or 4 days after infection. As expected, parvoviruses proved 
to be sensitive to I FN-a  or 7 [revealed by an inhibition of  the cytopathic effect 
(CPE) of MVM infection in L929 cells and of that of  H-1 infection in HeLa cells 
(data not shown)]. These observations are in line with the results of  others 
reporting sensitivity of  parvovirus MVM to IFN (e.g., Harris et al. 1974). 
In additional experiments we used THP-1, HeLa or RAW 264 cells, to test for 
an induction of  TNF  or of  IL-6 after infection with AAV or H-1, respectively. As 
shown in Fig. 2, parvovirus infection (AAV type 2; H -1) led to a limited induction 
of TNF  in THP-1 (Fig. 2a) or RAW264 (Fig. 2b) cells, similar to the stimulation 
with l ipopolysaccharide (LPS; positive control) as measured by ELISA. In 
adsorption for 30 min at 37 o C) at an m.o.i, of 50 pfu/cell (AAV type 2), of 500 pfu/cell (H- 1, AAV 
type 5). Uninfected or LPS-treated cells were used as controls. After 16 h, supernatant ofthe cells 
was removed and (after low-speed centrifugation) analyzed for the presence of TNF. Induction of 
TNF was measured by analysis of the concentration f TNF in the supernatant of treated or 
infected cells using ELISA (a). Analyses by bioassay [cytotoxicity on murine fibroblasts as 
described by M~innel & Falk (M~innel and Falk, 1989)] are presented in a and b. (Mouse TNF 
could only be measured by bioassay) 
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bioassays, however, no induction of TNF by parvovirus infection was found in 
THP-1 cells, whereas a slight enhancement of the level of LPS-induced TNF 
synthesis could be observed (Fig. 2a, b). Similar results were obtained in HeLa, 
HL60 and U937 cells (data not shown). In parallel to the absence of IFN-]3 
induction, parvovirus infection also failed to induce synthesis of IL-6 in HeLa 
(Fig. 3) or THP-1 cells (not shown). In some experiments, however, a slight 
increase of TNF (positive control)-induced IL-6 synthesis was observed. 
Discussion 
The tumor-suppressive effects of parvovirus infections on a variety of tumors at 
different sites and of different origin (i.e., irrespective of the mode of tumor 
induction and of the transforming agent), suggest arather unspecific action of viral 
functions on tumor cells. Since a general stimulation by parvovirus infection of the 
host's immune system seems unlikely (cf. references cited above), we tested in 
assays in vitro whether parvovirus infections would possibly lead to the induction 
of IFN or other physiological response modifiers to many virus infections, known 
to interfere also with tumor cell growth (cf., Clemens and McNurlan 1985; Sehgal 
et al. 1989; Billiau et al. 1991; Loetscher et al. 1991). We were able to show in very 
sensitive cell culture assays (measuring the induction of the IFN-]3 promoter) that 
neither autonomously replicating parvoviruses (MVM, H-l) nor AAV induced 
IFN-[3 in rodent or human cells; since factors or agents inducing the expression of 
IFN-~ also induce IFN-13 it is conceivable that IFN-a is likewise not induced by 
parvovirus infection. This is in line with the findings of a weak IFN induction in 
vivo. Although parvovirus MVM has been reported to induce IFN in infected mice 
(Harris et al. 1974), the levels of IFN induced were relatively low [IFN was 
measured by the yield reduction of mouse polio virus (strain GD-7) HA in L929 
cells]. The low levels of IFN seen with MVM, a single-stranded DNA virus, were in 
contrast with those observed with the single-stranded RNA virus, EMC (Harris et 
al. 1974). In the same study, MVM was shown to be very sensitive to the (virus-) 
inhibiting action of IFN. 
These results are consistent with the study of Kilham et al. (1968) in which 
Kilham rat virus (KRV) was shown to induce only very low levels of IFN as 
detected in serum specimens from infected rats. Similar results were reported 
by Darrigrand et al. (1984) showing that KRV did not induce measurable 
serum IFN in infected rats. Also in these studies, KRV was sensitive to the 
antiviral effect of IFN. The mink parvoviruses, Aleutian disease virus (ADV) 
and mink enteritis virus (MEV) neither induced nor were sensitive to the 
effects of IFN (Wiedbrauk et al. 1986). Furthermore, these authors reported 
that preexisting parvovirus infections did not inhibit poly(I) poly(C)-induced 
IFN production. 
MVM was found to inhibit various functions mediated by murine T cells in 
vitro. These included inhibition of lymphocyte proliferation and generation of 
cytolytic T lymphocyte activity but not IFN-ct or y induction (Engers et al. 1981). 
However, from some of their results, the authors suggest hat pretreating cell 
cultures with exogenous murine IFN-ct or y does not inhibit the replication of 
MVM. 
It might be possible that the known influences of parvovirus infection on the 
cell cycle (Winocour et al. 1988; Klein-Bauernschmitt et al. 1992) are involved in 
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the inefficient induction of cytokine synthesis under the conditions described 
herein. 
In our study, lytically replicating parvoviruses (MVM, H-1) were demonstrat- 
ed to be sensitive to the antiviral action of IFN-a or ~, in human and murine cell 
lines. This sensitivity of MVM to the antiviral effects of IFN has been observed also 
by others (Harris et al. 1974). However, these results are at variance with the report 
by Engers et al. (1981). 
Our results demonstrate in addition that parvoviruses may be weak inducers 
of the cytokines TNF or IL-6 in the cell cultures tested. In some experiments, a 
slight increase of the expression of these cytokines was observed when cells treated 
with potent inducers were additionally infected with parvoviruses. Thus, it is 
conceivable that parvovirus infection "assists" in the synthesis of cytokines. 
The results reported herein do not definitely exclude that induction of IFN 
might play some role in parvovirus-mediated umor suppression i vivo. However, 
the apparent inability of the parvoviruses used in this study to induce detectable 
levels of IFN in vitro as well as the very weak induction observed in vivo make this 
unlikely. 
Further in vivo investigations might well clarify whether the slight enhance- 
ment of synthesis of cytokines when induced by other agents could contribute to 
the rather unspecific tumor-suppressive properties of parvoviruses. This study 
does not reveal mechanisms by which parvoviruses can act as antitumor agents. 
Our findings make it rather unlikely that an induction of cytokines plays an 
important role in the observed tumor-suppressive properties of these agents. 
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